Company news: Boehringer Ingelheim, GlaxoSmithKline

Share this article:
Boehringer Ingelheim's foray into oncology meds now includes a five-year collaboration agreement with personalized medicine specialist Horizon Discovery. The agreement gives Boehringer access to its Discovery Toolbox, which will profile the drug maker's compounds, and Genesis, Horizon's genome editing technology to help develop human isogenic disease model cells. Horizon said the technology will help develop “high quality cell lines” that model disease-causing mutations.

Months after its Human Genome Sciences buy, GlaxoSmithKline has submitted a BLA for albiglutide, a pipeline diabetes 2 therapy. GSK gained full ownership of the therapy with its HGS acquisition, along with ownership of Benlysta and darapladib. The experimental drug, which is being developed as a weekly shot, is a GLP-1 agonist, much like Amylin's weekly Bydureon.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.